NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.
A curation working group established a framework that considers the nature and strength of the available evidence when evaluating gene-disease associations.
The collaborators are each providing funding and samples, and plan to study about 100 patients with a subset of Castleman disease to identify biomarkers.
NIH researchers got tantalizingly close to long-term engraftment at levels that could provide a clinical benefit in gene therapy applications.
With tens of thousands of immune cell measurements for almost 500 individuals, researchers saw enhanced genetic influence over some adaptive immune traits.
The team identified gene expression patterns that can determine how severe a patient's systemic sclerosis is and if treatment has been effective.
Researchers working on the Human Functional Genomics Project have begun to unravel genetic relationships and variations in human immune response.
The company's approach investigates the utility of high-density lipoproteins as molecular markers for multiple diseases, starting with cardiovascular.
The Human Immunome Program, which is part of the Human Vaccines Project, eventually plans to profile B-cell and T-cell receptors in more than 1,000 individuals.
The new study in NEJM describes six families that share a disorder caused by mutations in IKAROS, a protein that plays a role in immune cell development.
360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.
The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.
In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.
Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.